These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20722750)

  • 1. The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.
    Israr M; Mitchell D; Alam S; Dinello D; Kishel JJ; Meyers C
    HIV Med; 2011 Mar; 12(3):145-56. PubMed ID: 20722750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the HIV protease inhibitor amprenavir on the growth and differentiation of primary gingival epithelium.
    Israr M; Mitchell D; Alam S; Dinello D; Kishel JJ; Meyers C
    Antivir Ther; 2010; 15(2):253-65. PubMed ID: 20386081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the HIV nucleoside reverse transcriptase inhibitor zidovudine on the growth and differentiation of primary gingival epithelium.
    Mitchell D; Israr M; Alam S; Kishel J; Dinello D; Meyers C
    HIV Med; 2012 May; 13(5):276-90. PubMed ID: 22276657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium.
    Mitchell D; Israr M; Alam S; Dinello D; Kishel J; Jia R; Meyers C
    HIV Med; 2014 Apr; 15(4):196-202. PubMed ID: 24580719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does lopinavir/ritonavir alter the primary gingival epithelium?
    Rivero A; Pérez-Camacho I
    Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1345-9. PubMed ID: 21133660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lopinavir-Ritonavir: a new protease inhibitor.
    Mangum EM; Graham KK
    Pharmacotherapy; 2001 Nov; 21(11):1352-63. PubMed ID: 11714208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encouraging resistance data for Kaletra (lopinavir/ritonavir).
    J Assoc Nurses AIDS Care; 2002; 13(3):108. PubMed ID: 12064017
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
    Noor MA; Flint OP; Maa JF; Parker RA
    AIDS; 2006 Sep; 20(14):1813-21. PubMed ID: 16954722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug resistance test shows encouraging results.
    AIDS Alert; 2002 Feb; 17(2):17-8, 13. PubMed ID: 11862740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers.
    Pao VY; Lee GA; Taylor S; Aweeka FT; Schwarz JM; Mulligan K; Schambelan M; Grunfeld C
    AIDS; 2010 Jan; 24(2):265-70. PubMed ID: 19890203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.
    Croxtall JD; Perry CM
    Drugs; 2010 Oct; 70(14):1885-915. PubMed ID: 20836579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Oldfield V; Plosker GL
    Drugs; 2006; 66(9):1275-99. PubMed ID: 16827606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.
    Wu X; Sun L; Zha W; Studer E; Gurley E; Chen L; Wang X; Hylemon PB; Pandak WM; Sanyal AJ; Zhang L; Wang G; Chen J; Wang JY; Zhou H
    Gastroenterology; 2010 Jan; 138(1):197-209. PubMed ID: 19732776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolic effects of lopinavir/ritonavir in HIV-negative men.
    Lee GA; Seneviratne T; Noor MA; Lo JC; Schwarz JM; Aweeka FT; Mulligan K; Schambelan M; Grunfeld C
    AIDS; 2004 Mar; 18(4):641-9. PubMed ID: 15090769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.
    Song I; Min SS; Borland J; Lou Y; Chen S; Patel P; Ishibashi T; Piscitelli SC
    J Clin Pharmacol; 2011 Feb; 51(2):237-42. PubMed ID: 20489027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.
    Hills-Nieminen C; Hughes CA; Houston S; Shafran SD
    Ann Pharmacother; 2009 Dec; 43(12):2117-20. PubMed ID: 19934385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of protease resistance during simplification therapy with lopinavir/ritonavir alone.
    Sprinz E; Jeffman M
    HIV Clin Trials; 2007; 8(2):105-6. PubMed ID: 17507327
    [No Abstract]   [Full Text] [Related]  

  • 20. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.